Reassessment of the prognostic factors of international prognostic index (IPI) in the patients with diffuse large B-cell lymphoma in an era of R-CHOP in Chinese population

Annals of Hematology

Volumn 88, Issue 9, 2009, Pages 863-869

  Yang, Shen ^a   Yu, Yao ^a   Jun Min, Li ^a   Jian Qing, Mi ^a   Qiu Sheng, Chen ^a   Yu, Chen ^a   Wei Li, Zhao ^a   Jian Hua, You ^a   Hui Jin, Zhao ^a   Yan, Wang ^a   Li, Wang ^a   Shu, Cheng ^a   Zhi Xiang, Shen ^a  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

Bulky disease; Complete response; Diffuse; Large B cell; Lymphoma

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; LACTATE DEHYDROGENASE; PREDNISONE; RITUXIMAB; VINCRISTINE;

ADULT; AGED; ARTICLE; B CELL LYMPHOMA; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER REGRESSION; CANCER STAGING; CANCER SURVIVAL; CHINESE; CLINICAL ASSESSMENT TOOL; CONTINUOUS INFUSION; DISEASE ACTIVITY; DISEASE FREE SURVIVAL; DOSE RESPONSE; DRUG EFFICACY; DRUG MEGADOSE; FEMALE; HUMAN; INTERNATIONAL PROGNOSTIC INDEX; LACTATE DEHYDROGENASE BLOOD LEVEL; LARGE CELL LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS;

ADOLESCENT; ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYCLOPHOSPHAMIDE; DISEASE-FREE SURVIVAL; DOXORUBICIN; FEMALE; HUMANS; LYMPHOMA, LARGE B-CELL, DIFFUSE; MALE; MIDDLE AGED; PREDNISONE; PROGNOSIS; VINCRISTINE; YOUNG ADULT;

EID: 67949106658     PISSN: 09395555     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00277-009-0702-1     Document Type: Article

References (29)

1. Coiffier B (1997) Non-Hodgkin's lymphomas. In: Cavalli F, Hansen HH, Kaye SB (eds) Textbook of medical oncology. Martin Dunitz, London, pp 265-287
2. Chen Y, Du H, Hu WW et al (2004) Clinicopathologic analysis and classification of 365 cases of non-Hodgkin's lymphomas according to the new WHO criteria. Chinese J Diagn Pathol 11:304-307
3. Zhang YN, Zhou XG, Zhang SH et al (2005) Clinicopathologic study of 369 B-cell non-Hodgkin lymphoma cases, with reference to the 2001 World health organization classification of lymphoid neoplasms. Zhonghua Bing Li Xue Za Zhi 34(4):193-197
4. Chuang SS, Lin CN, Li CY (2000) Malignant lymphoma in southern Taiwan according to the revised European-American classification of lymphoid neoplasms. Cancer 89:1586-1592 doi: 10.1002/ 1097-0142(20001001)89:7<1586::AID-CNCR24>3.0.CO;2-1
5. Coiffier B, Lepage E, Briere J et al (2002) CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 346:235-242 doi: 10.1056/NEJMoa011795
6. Pfreundschuh M, Trumper L, Osterborg A et al (2006) CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: A randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol 7:379-391 doi: 10.1016/S1470-2045(06)70664-7
7. Pfreundschuh M, Kloess M, Zeynalova S et al (2006) Six vs. eight cycles of bi-weekly CHOP-14 with or without rituximab for elderly patients with diffuse large B-cell lymphoma (DLBCL): Results of the completed RICOVER-60 trial of the German high-grade non-Hodgkin's lymphoma study group (DSHNHL). Blood 10864a abstract 205
8. Sehn LH, Donaldson J, Chhanabhai M et al (2005) Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia. J Clin Oncol 23(22):5027-5033 doi: 10.1200/JCO.2005.09.137
9. Coiffier B (2005) Treatment of diffuse large B-cell lymphoma. Curr Hematol Rep 4(1):7-14
10. Habermann TM, Weller EA, Morrison VA et al (2003) Phase III trial of rituximab-CHOP (R-CHOP) vs. CHOP with a second randomization to maintenance rituximab (MR) or observation in patients 60 years of age and older with diffuse large B-cell lymphoma (DLBCL). Blood 102:6A
11. Moore DF Jr, Cabanillas F (1998) Overview of prognostic factors in non-Hodgkin's lymphoma. Oncology 12(10):17-24
12. A predictive model for aggressive non-Hodgkin's lymphoma: The International Non-Hodgkin's Lymphoma Prognostic Factors Project. N Engl J Med 329:987-994 doi: 10.1056/NEJM199309303291402
13. Jaffe ES, Harris NL, Stein H, Vordiman JW Pathology and genetics of tumours of haematopoietic and lymphoid tissues. World Health Organization Classification of Tumours. Lyon: IARC, 2001
14. Wilder RB, Rodriguez MA, Medeiros LJMD (2002) International prognostic index-based outcomes for diffuse large B-cell lymphomas. Cancer 94(12):3083-3088 doi: 10.1002/cncr.10583
15. Hochster HS, Weller E, Ryan T et al (2004) Results of E1496: A Phase III trial of CVP with or without maintenance rituximab in advanced indolent lymphoma (NHL). Proc Am Soc Clin Oncol 23:556
16. Czuczman MS, Fallon A, Mohr A et al (2002) Rituximab in combination with CHOP or fludarabine in low-grade lymphoma. Semin Oncol 29(1):36-40 doi: 10.1053/sonc.2002.30152
17. Sehn LH, Berry B, Chhanabhai M et al (2007) The revised international prognostic index (r-ipi) is a better predictor of outcome than the standard ipi for patients with diffuse large B-cell lymphoma treated with R-CHOP. Blood 109(5):1857-1861 doi: 10.1182/blood-2006-08-038257
18. Good clinical practice for trials on medicinal products in the European community. Good Clin Pract J 1:SUppl
19. Cheson BD, Horning SJ, Coiffier B et al (1999) NCI-sponsored international working group. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. J Clin Oncol 17:1244
20. Chen Y, Du H, Hu WW et al (2004) Clinicopathologic analysis and classification of 365 cases of non-Hodgkin' s lymphomas according to the new WHO criteria. Chinese J Diagn Pathol 11:304-307
21. Zhang YN, Zhou XG, Zhang SH et al (2005) Clinicopathologic study of 369 B-cell non-Hodgkin lymphoma cases, with reference to the 2001 world health organization classification of lymphoid neoplasms. Zhonghua Bing Li Xue Za Zhi 34(4):193-197
22. Xiao C, Su ZL, Wu QL et al (2005) Clinical and pathological reassessment of 493 cases of non-Hodgkin's lymphomas according to current WHO classification of lymphoid neoplasms. Zhonghua Bing Li Xue Za Zhi 34(1):22-27
23. Yin HF, Li T, Li JX (2003) Retrospective analysis of 304 cases of malignant lymphomas in pathology: Study and practice of the WHO classification of lymphoid neoplasms. Zhonghua Yi Xue Za Zhi 83(18):1556-1560
24. Zhang HY, Lin TY, Jiang WQ et al (2004) Clinical analysis of rituximab combined with chemotherapy in treating aggressive B-cell non-Hodgkin's lymphoma. Chin J Cancer 23(12):1681-1686
25. Lin TY, Zhang HY, Huang Y et al (2005) Comparison between R-CHOP regimen and CHOP regimen in treating naive diffuse large B-cell lymphoma in China - a multi-center randomized trial. Ai Zheng 24(12):1421-1426
26. Philip T, Guglielmi C, Hagenbeek A et al (1995) Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N Engl J Med 333:1540-1545 doi: 10.1056/NEJM199512073332305
27. Gianni AM, Bregni M, Siena S et al (1997) High-dose chemotherapy and autologous bone marrow transplantation compared with MACOP-B in aggressive B-cell lymphoma. N Engl J Med 336:1290-129 doi: 10.1056/ NEJM199705013361804
28. Milpied N, Deconinck E, Gaillard F et al (2004) Initial treatment of aggressive lymphoma with high-dose chemotherapy and autologous stem-cell support. N Engl J Med 350:1287-1295 doi: 10.1056/NEJMoa031770
29. Corradini P, Ladetto M, Zallio F, Astolfi M, Rizzo E, Sametti S et al (2004) Long-term follow-up of indolent lymphoma patients treated with high-dose sequential chemotherapy and autografting: Evidence that durable molecular and clinical remission frequently can be attained only in follicular subtypes. J Clin Oncol 22:1460-1468 doi: 10.1200/ JCO.2004.10.054